The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Sagar Doshi of Nuvama Professional Clients Group recommends these three stocks today- Oil and Natural Gas Corporation Ltd ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

The capital market regulator, in its January 2 order, barred both Parekh and Singapore-based Rohit Salgaocar, who was a ...

Elara Securities has a 'Buy' rating with a target of Rs 1,088 on Tata Motors. Nuvama has 'Reduce' rating on Tata Motors and a ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...